The innate immune system, which includes mannose-binding lectin (MBL), recognizes a broad range of molecular patterns on a broad range of infectious agents and is able to distinguish them from self. MBL is a liver-derived serum protein and is secreted into the serum, where it can activate an immune response before the induction of antigen-specific immunity. Circumstantial evidence in human populations suggests that low serum levels of MBL predispose to infection. To analyze the role of MBL in vivo, we created MBL-null mice and challenged these mice with infection under various conditions. Our results suggest that MBL plays an important role as a first-line host defense against certain infectious agents. In addition, it is likely that MBL is a key regulator of inflammation beyond expected roles in the infection.
The ability to respond to infectious agents is a prerequisite for the survival of multicellular organisms. Recent findings indicate that the basic tenets of mammalian first-line host defenses have their origin in primitive life forms. Remarkably, a set of protein motifs and structures are conserved from plants through insects to humans. Broadly speaking, host defense-associated protein domains either are involved in the recognition of infectious agents or play a role in signaling. The Tolllike receptors are a recent example of such pattern recognition molecules. Toll-like receptors were first described in the context of embryonic development in Drosophila species [1] but were noted to have a cytoplasmic domain that bore homology to the IL-1 receptor [2] . The connection between these Toll/IL-1 receptor domains and the putative ligand recognition leucine-rich repeat domains led to the identification of at least 10 mammalian Toll-like receptors that play a role in sensing infectious agents [3, 4] .
This concept that was applied to Toll-like receptors had precedent. The identification of mammalian lectinlike domains and the discovery that the C-type lectin family play a role in host defense led to the identification of homologous domains in primitive life forms [5] . The presence of a lectin domain within a protein leads to the conjecture that the lectin-containing molecule may be involved in recognition of carbohydrate ligands on the surfaces of infectious agents. This assumption is almost entirely based on structure function analysis of the mammalian mannose-binding lectin (MBL), which is involved in innate immunity [5] . Of note, recent comparative analyses of C-type lectin domains illustrate that this domain is abundant in metazoans, but only about half of the proteins bind carbohydrates in a calcium-dependent manner [5, 6] . C-type lectins containing proteins, such as MBL, play a key role in innate immunity. Here, we review the characteristics of MBL and their genetic regulation, discuss correlation studies of low levels of MBL with susceptibility to infection, and put these findings into the context of an experimental system to demonstrate that the MBL is a key first-line molecule against certain infectious agents.
CHARACTERISTICS OF THE MBL
MBL is a liver-derived serum protein. It has an aminoterminal cysteine-rich domain followed by collagen repeats and a neck domain that orients the carboxylterminal carbohydrate recognition domains (figure 1) [7] . The carbohydrate recognition domains in human MBL are 45 Å apart. The protein circulates as oligomers of trimers with the highest-order oligomer as a hexamer of trimers. MBL appears to be a prototypical pattern recognition molecule that is able to recognize a wide range of microorganisms. Infectious agents recognized by MBL include gram-positive and gramnegative bacteria, yeasts, parasites, mycobacteria, and viruses [8] . Of importance, MBL seems to be able to distinguish nonself from species self or altered self, although it is able to recognize dying cells [9, 10] . The specificity that allows the distinction of surfaces of virally infected cells and transformed cells from normal host cells depends both on fine recognition of molecular micropatterns and on the spatial geometry of macropattern (figure 1). The cognate ligands recognized by MBL appear to be dictated by the spatial orientation of the carbohydrate-binding domains and the differences in geometry of the sugars that decorate microorganisms, versus host glycoproteins that are exposed on viable cells (figure 1).
MBL is able to activate complement via a novel mechanism that co-opts the MBL-associated serine protease (MASP) [11, 12] . There is a family of 3 related MASP genes, but MASP-2 uses the classical pathway convertase to cleave the third complement component (C3) [12] . MBL therefore activates complement in an antibody-independent manner. The analogy of MBL to antibodies extends the function of MBL as an opsonin, as illustrated in figure 2 . The enhancement of phagocytosis by MBL can occur by activation of complement, thereby enhancing uptake of MBL-bound microorganisms via complement receptors (figure 2). Alternatively, complexes of MBL bound to microorganisms can bind directly to phagocytic cells via collectin receptors [13] , which trigger internalization of the bound complex.
POLYMORPHISMS IN THE MBL GENE AND DISEASE ASSOCIATIONS
The idea that a relative lack of MBL might predispose the host to infection was based on the description of an MBL-dependent opsonic defect in human serum that correlated with a phenotype of recurrent infection. Patients were found to have 1 of 3 substitution single-nucleotide polymorphisms in exon 1 of the MBL gene that disrupt the collagen helix [14] . Recent experiments using circular dichroism and differential scanning calorimetry demonstrate that the collagen region of proteins that contain 3 coding single-nucleotide polymorphisms in the collagen region leave this domain intact, although more easily unfolded [15] . More detailed analysis of the MBL gene has revealed at least 10 distinct MBL haplotypes in humans, 4 of which (LYPB, LYQC, HYPD, and LXPA) dictate low serum levels [16] . Interestingly, various human populations show a high rate of haplotype variation, with a range of heterozygosity from 15% in white populations to 30% in certain African populations [17, 18] . Recent analysis reveals a further 6 singlenucleotide polymorphisms in the MBL gene (J. Landers, personal communication). This complexity in the MBL locus suggests the association of variations in MBL levels, as dictated by certain haplotypes and susceptibility or resistance to infection.
A survey of the literature found 29 studies attempting to correlate the presence of single-nucleotide polymorphisms or low MBL levels with susceptibility to infections (table 1). In all of these studies, the patient populations were heterozygous with regard to the exact cutoff level that defined "low MBL levels." Furthermore, it appears that MBL is a gene modifier for patients with cystic fibrosis, because, in such patients, low MBL levels result in a significantly worse prognosis. In addition, low MBL levels in patients correlate with development of systemic inflammatory response syndrome. It has been postulated that MBL might have a protective role against intracellular organ- isms. In fact, this was confirmed by 3 independent studies (table 1). Low MBL levels have also been associated with susceptibility to autoimmune diseases (table 1) .
The net result of these studies indicates that MBL plays a role in limiting the infection of certain pathogens, but the high rates of haplotypes that specify low MBL levels in certain ethnic groups suggest that a relative lack of MBL might be beneficial to the host under other circumstances. Recent studies indicate that the MBL-MASP pathway may play a critical role in mediating ischemic reperfusion injury in the heart. By implication, persons who lack MBL may be afforded relative protection against the complications of myocardial infarction [46] .
MBL-DEFICIENT MICE ARE HIGHLY SUSCEPTIBLE TO INFECTION WITH STAPHYLOCOCCUS AUREUS
To provide formal proof that MBL is important in host defense in vivo, we set out to create a mouse model of MBL deficiency. Humans and New World monkeys have a single MBL gene, whereas rodents have 2 homologous forms of MBL, which are designated MBL-A and MBL-C, the respective gene products of the mbl1 and mbl2 genes, and are 50% homologous [47] [48] [49] . These 2 homologous proteins have distinct and overlapping binding specificities, are found predominantly in serum, and are able to bind MASPs to activate complement [49] [50] [51] . The relative physiological role of these proteins in vivo has not been clearly defined. To address some of these questions, we created MBL-A-and MBL-C-double knockout (MBL-null) mice. We verified that the MBL-null mice lack MBL in serum and, therefore, have a nonfunctional MBL complement pathway [52] . We found that MBL-null mice died 2 days after intravenous inoculation with S. aureus, compared with 55% survival of wild-type mice (figure 3). Of importance, pretreatment of the MBL-null mice with recombinant human MBL reversed the phenotype ( figure 3 ). In keeping with the role of MBL as an opsonin, we found significantly more bacteria in the blood of MBL-null mice than in that of wild-type mice at 24 h after inoculation [52] . In addition, the viscera of MBLnull mice accumulated significantly more bacteria than did the viscera of wild-type mice 24 h after inoculation [52] . Further- more, our results indicated a decrease in phagocytosis of bacteria in blood and peritoneal cavity in MBL-null mice, thereby providing a mechanism for decreased clearance of bacteria in MBL-null mice in vivo [52] .
Several studies (table 1) show a correlation between MBL haplotypes that specify low levels of MBL and risk of infection in patients with cancer who have chemotherapy-induced neutropenia. We set out to test this idea in a neutropenic mouse model that mimics patients with cancer who are going through chemotherapy. In this model, mice were rendered neutropenic by 2 intraperitoneal injections of cyclophosphamide, resulting in profound neutropenia by day 4 after treatment. At this time, wild-type and MBL-null mice were inoculated with S. aureus. By day 10 after inoculation, 72.4% (21/29) of MBL-null mice developed abscesses in multiple organs, compared with 20% (3/15) of wild-type mice (table 2) . Bacterial loads in organ revealed that neutropenic MBL-null mice displayed enhanced bacterial accumulation in organs, compared with wild-type mice [52] .
CONCLUSIONS
MBL appears to fulfill the criteria as an important host defense molecule against initial infection with S. aureus. The animal data indicate that MBL acts in serum as an opsonin. The effector mechanism appears to be mediated, in part, by MBL-dependent phagocytosis by leukocytes. On the basis of these studies, it is not clear whether MBL-dependent clearance of S. aureus is mediated via complement receptors or MBL (collectin) receptors. Unpublished observations from our laboratory indicate that there is indeed an MBL-dependent, complement-independent clearance mechanism.
A synergistic interaction between neutrophils and MBL is suggested by clinical observations that patients with chemotherapy-induced neutropenia with haplotypes that specify low serum MBL levels appear to be more susceptible to infection [25, 26, 29] . These clinical observations, together with in vitro studies, suggest that MBL plays a key role in first-line host defense [53] and support a role for MBL in combating infection in vivo. It is also seems logical that a combination of granulocyte colony-stimulating factor and MBL may be a logical therapeutic approach for patients with cancer who have neutropenia.
The question remains as to why the MBL locus displays such a degree of variation. We postulate that MBL is not merely an opsonin but a pivotal molecule in regulating inflammation. MBL targets seem to extend beyond microbial surfaces. For example, ischemic reperfusion injury in certain tissues, such as the heart, exposes ligands that are recognized by MBL. A consequence of this recognition may be activation of the MBL-MASP complement pathway, compounding the tissue injury. Accordingly, low MBL levels decrease the activity of the MBL complement pathway, resulting in a response that is less proinflammatory and, therefore, less injurious to the host. It is interesting that ethnic groups who have haplotypes indicating low levels of MBL also have a low incidence of heart disease.
Overall, MBL is an important host defense molecule that plays a key role in first-line host defense against certain infectious agents. However, it is also likely that the role of MBL extends beyond this restricted infection-related view in that it appears to be a key regulator of inflammation.
